Sobi co-founder thinks acquisition is likely after USD 8bn bid

Today’s takeover bid for Sobi is likely to end in deal that will create rapid growth, assesses co-founder, former CEO and previous chairman Bo Jesper Hansen.

Bo Jesper Hansen, co-founder of Sobi | Photo: Ritzau Scanpix/STF/Thomas Lekfeldt

Everything indicates that a bid of over USD 8bn (DKK 50bn) for Swedish Sobi from the American private equity firm Advent and Singapore's state private equity fund, GIC, through the joint company Agnafit Bidco, will end in an acquisition.

This is the assessment of Bo Jesper Hansen, a Danish biotech specialist who founded the company 30 years ago, and has previously acted as both CEO and chairman of the board.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs